INDEPENDENT THINKING. WHOLE-FOOD LIVING.NO ANIMALS / NO OIL
THENANODIET
← THE STUDY LIBRARY

Systematic review / meta-analysis / 2017

Niacin therapy did not reduce mortality or cardiovascular events in people with or at risk of CVD and increased side effects.

A systematic review and meta-analysis of 23 RCTs involving 39,195 participants evaluated niacin monotherapy or add-on therapy (median dose 2 g/day, median duration 11.5 months). Niacin did not reduce overall mortality (RR 1.05, 95% CI 0.97 to 1.12), cardiovascular mortality (RR 1.02, 95% CI 0.93 to 1.12), non-cardiovascular mortality (RR 1.12, 95% CI 0.98 to 1.28), fatal or non-fatal myocardial infarctions (RR 0.93, 95% CI 0.87 to 1.00), or strokes (RR 0.95, 95% CI 0.74 to 1.22). Participants receiving niacin were significantly more likely to discontinue treatment due to side effects compared to control (RR 2.17, 95% CI 1.70 to 2.77).

Study type
Systematic review and meta-analysis of RCTs
Who was studied
39,195 participants (mean age 33 to 71 years) across 23 RCTs with or at risk of CVD
What was measured
Overall mortality, cardiovascular mortality, myocardial infarction, stroke, and side effects

THE PAPER

Niacin for primary and secondary prevention of cardiovascular events.

Schandelmaier S, Briel M, Saccilotto R, Olu KK, Arpagaus A, Hemkens LG, Nordmann AJ. Cochrane Database Syst Rev, 2017.

PubMed 28616955 ↗DOI 10.1002/14651858.cd009744.pub2 ↗

Heart & arteriesNutrients & adequacy

This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.